Tauriga Sciences, Inc.

Tauriga Sciences Inc. Appoints University of Cincinnati Biochemistry Professor Daniel J. Hassett, Ph.D. as Member of Company's Scientific and Medical Advisory Board

| Source: Tauriga Sciences Inc

CINCINNATI, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or the "Company"), a diversified life sciences company, has today announced the appointment of Dr. Daniel Hassett ("Dr. Hassett") as a member of the Company's Scientific and Medical Advisory Board. Dr. Hassett was the Co-Founder and Chairman of the Scientific Advisory Board of Pilus Energy LLC ("Pilus Energy") prior to Tauriga's acquisition of wholly-owned subsidiary Pilus Energy on January 28, 2014. Dr. Hassett's microbiology expertise is of great importance as the Company advances its five-phase commercial pilot test with the EPA's Test and Evaluation facility and the Metropolitan Sewer District of Greater Cincinnati to scale up Pilus Energy's synthetic biology platform for generating value from wastewater.

Tauriga's Chairman & CEO Dr. Stella Sung commented, "The Company is fortunate to have recruited Dr. Daniel Hassett to its Scientific and Medical Advisory Board. Not only is Dr. Hassett one of the foremost experts on the specific microorganisms used in the proprietary Pilus Energy technology, but he is conveniently located in Cincinnati, near our commercial pilot test site. I believe Dr. Hassett's involvement in Tauriga will create shareholder value by continuing to build and expand Pilus Energy's capabilities and market opportunities."

Newly appointed Scientific and Medical Advisory Board member Dr. Daniel Hassett stated, "I am enthusiastic about the progress that Pilus Energy has made since it was acquired by Tauriga, and I look forward to providing my advice and expertise in selecting and enhancing specific bacterial strains for optimizing the Pilus 'wastewater to value' platform."

Please see below bio Daniel J. Hassett, PhD:

Currently a fully tenured professor of molecular genetics, biochemistry, and microbiology at the University of Cincinnati, College of Medicine. Dr. Hassett is an award-winning expert on cystic fibrosis, particularly as it relates to infectious microorganism. He is a frequent invited speaker, convener, and symposia presenter with over 100 scientific events thus far. He has participated in the thesis defense and/or doctoral exams for nearly thirty graduate students. Dr. Hassett manages a lab and has gained over $15M in grants and donations as a research leader.

He is a journal reviewer for the following 19 journals (in alphabetic order): Applied and Environmental Microbiology, Cell, Cell-Host and Microbe, Free Radical Biology and Medicine, Frontiers in Microbiology, Gene, Infection and Immunity, Journal of Bacteriology, Journal of Biological Chemistry, Journal of Clinical Investigation, Letters in Applied Microbiology, Microbial Pathogenesis, Microbiology, Molecular Microbiology, Plant-Microbe Interactions, PloS Medicine, Proceedings of the National Academy of Sciences, Science, Trends in Microbiology Reviews.

His intellectual property developments include: 1. Streaking Jack Inoculator. A device that isolates single bacterial colonies from a mixed population in 5 seconds. With U.C. and Bell-Art Scientific. 2. OprF, a biomarker for cystic fibrosis lung disease and an anaerobic drug target. 3. Use of nitrite composition to kill pathogenic bacteria during airway and abscess infections. Aires Pharmaceuticals, San Diego, CA, November 2006, Toxicology completed, 8-07; Phase I human trials completed August 2008. Phase II trials-anticipated start, October 2008.

Professor Hassett has to his credit over 130 journal articles and/or reviews.

About Tauriga Sciences, Inc.:

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. On July 10, 2014, Tauriga acquired a Honeywood LLC, a California based topical cannabis lotion company. Please visit the Company's corporate website at www.tauriga.com.


This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.


Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

Tauriga Sciences, Inc.:
Dr. Stella M. Sung,
Chairman and Chief Executive Officer
Tauriga Sciences, Inc.
San Diego: + 1-858-353-5749
Montreal: + 1-514-840-3697